Loading...
Please wait while we get things ready for you
Please wait while we get things ready for you
President Trump signed an executive order Monday that would fundamentally reshape America's childhood immunization landscape, slashing the number of universally recommended vaccines from 17 down to 11 and ordering the combined MMR shot split into three separate single-disease vaccines to be administered at individual visits. The "Gold Standard Childhood Vaccine Recommendations" directive also reclassified RSV monoclonal antibodies, hepatitis A, hepatitis B, and meningococcal...
The FDA has approved the first-ever mRNA-based seasonal flu vaccine for adults 50 and older, leveraging the same groundbreaking technology used in COVID-19 shots to fight influenza. Moderna's mFLUSIVA cleared the regulatory hurdle on August 5, marking a significant milestone in vaccine technology adaptation.
Key numbers from this week's FDA actions:
A new observational study published in JAMA Network Open suggests that GLP-1 medications like Ozempic and Mounjaro may significantly reduce the risk of fragility fractures in people with type 2 diabetes, with the largest reductions seen in hip, femur, and spine fractures.
These popular weight-loss and diabetes drugs might also be protecting bones. The study found patients taking GLP-1 drugs had fewer breaks from minor falls—a big deal because diabetes...
Eli Lilly (LLY) announced that its KRAS G12C inhibitor, olomorasib, has received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with the specific KRAS G12C mutation. This designation is a major regulatory fast-track, signaling the drug's potential to offer substantial improvement over existing treatments for this notoriously difficult-to-treat cancer.
The company also entered a new clinical trial collaboration with Amplia...
The FDA approved Moderna's mFlusiva, the first-ever mRNA-based seasonal flu vaccine, marking a historic expansion of the technology that transformed COVID-19 vaccination. The vaccine, approved for adults 50 and older, demonstrated a 26.6% relative efficacy improvement over standard flu shots in a Phase 3 trial of over 19,000 participants.
A New Mexico judge has ordered Meta to pay an additional $567 million to fund youth mental health services, bringing the company's total liability in the state's child safety case to a staggering $942 million. The ruling doesn't just hit the company's bottom line—it mandates product-level overhauls. Meta must now build an under-13 age prediction model within two years, treat uncertain-age accounts as minors by default, and delete personal data collected from users it cannot...
The U.S. Department of Veterans Affairs has launched the PIVOT trial (Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression), a multi-site study testing COMP360 psilocybin in veterans whose depression has failed to respond to conventional therapies. The trial, conducted in collaboration with COMPASS Pathways, will compare clinical outcomes across two different dosages of the psychoactive compound found in magic mushrooms.
Imagine...
The FDA has approved the first-ever mRNA flu vaccine, marking a potential shift in how the U.S. approaches seasonal influenza. Moderna's mFLUSIVA (mRNA-1010) won full approval for adults ages 50-64 and accelerated approval for those 65 and older, with a required postmarketing study to confirm effectiveness in seniors.
The FDA granted accelerated approval to Replimune's melanoma drug Tudriqev on Thursday, ending a regulatory saga that saw the therapy rejected twice. The oncolytic viral treatment, approved for advanced melanoma patients who failed prior immunotherapy, represents a hard-fought win for the Massachusetts biotech and desperate patients with limited options.
A Stanford-led study reveals that the tau protein disrupts mitochondria by forcing reverse electron transport, a reversal that spews reactive oxygen species and triggers inflammation—a key mechanism of neurodegeneration in Alzheimer's disease. Blocking this electron flip improved learning and memory in flies and mice, and analysis of human brain tissue suggests the same pathway could be a druggable target.
Tau normally helps keep brain cells' internal...
The FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine, for adults aged 50 and older. A Phase 3 trial of nearly 41,000 participants showed the vaccine is 26.6% more effective than standard-dose flu shots in preventing infection.
Think of this as the COVID vaccine tech repurposed for the flu. It's faster to produce—taking just two to three months from strain selection to rollout, half the time of traditional egg-based vaccines. The...
A drug-resistant fungus labeled an "urgent antimicrobial resistance threat" has now been detected in 23 states this year, with Texas reporting 715 cases—the highest in the nation. Candida auris, a yeast that can cause deadly infections, is spreading rapidly in hospitals and long-term care facilities, with Michigan (518 cases) and Illinois (379 cases) also seeing significant outbreaks. The CDC data reveals the fungus has now reached every major U.S. region.
##...